COVID-19 might have forced pharma to finally fully embrace digital comms, but it’s been a steep learning curve and expertise varies across the industry.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh